Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 2 , Pages 96-109 , March 2008

Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): The first twenty years

  • Gerda G. Fillenbaum

      Affiliations

    • Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC, USA
    • Geriatrics Research, Education, and Clinical Center, Veterans Administration Medical Center, Fulton Street, Durham, NC, USA
    • Corresponding Author InformationCorresponding author. Tel.: 919-660-7530; fax: 919-668-0453.
    • ,
  • Gerald van Belle

      Affiliations

    • Department of Biostatistics, University of Washington, Seattle, WA, USA
    • ,
  • John C. Morris

      Affiliations

    • Alzheimer’s Disease Research Center and Departments of Neurology, Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA
    • ,
  • Richard C. Mohs

      Affiliations

    • Eli Lilly and Company, Indianapolis, IN, USA
    • ,
  • Suzanne S. Mirra

      Affiliations

    • Department of Pathology, State University of New York Downstate Medical Center, Brooklyn, NY, USA
    • ,
  • Patricia C. Davis

      Affiliations

    • Northwest Radiology Consultants, Atlanta, GA, USA
    • ,
  • Pierre N. Tariot

      Affiliations

    • University of Arizona College of Medicine, Memory Disorders Center Banner Alzheimer’s Institute, Phoenix, AZ, USA
    • ,
  • Jeremy M. Silverman

      Affiliations

    • Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    • ,
  • Christopher M. Clark

      Affiliations

    • Department of Neurology and Alzheimer’s Disease Center, University of Pennsylvania, School of Medicine, Philadelphia, PA, USA
    • ,
  • Kathleen A. Welsh-Bohmer

      Affiliations

    • Bryan Alzheimer Disease Research Center, Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    • ,
  • Albert Heyman

      Affiliations

    • Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, NC, USA

References 

  1. Foerstl H, Howard R, Burns A, Levy R. ‘The strange mental state of an old man who thought he would be slaughtered’: an early report of dementia with delusion (1785). J Royal Soc Med. 1991;84:432–434
  2. Alzheimer A. Über einer eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatrie. 1907;64:146–148
  3. Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology. 1998;51:728–733
  4. National Center for Health Statistics. Health, United States, 2005 with chartbook on trends on the health of Americans. Hyattsville, MD: US Government Printing Office; 2005;
  5. Freedman VA, Martin LG, Schoeni RF. Recent trends in disability and functioning among older adults in the United States: a systematic review. JAMA. 2002;288:3137–3146
  6. Manton KG, Gu X, Lamb V. Change in chronic disability from 1982 to 2004/2005 as measured by long-term changes in function and health in the U.S. elderly population. PNAS. 2006;103:18374–18379
  7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed.. Washington, DC: American Psychiatric Association; 1980;
  8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association; 1987;
  9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed.. Washington, DC: American Psychiatric Association; 1994;
  10. Health Care Financing Administration. The International Classification of Diseases, 9th revision, clinical modification: ICD-9-CM. 2nd ed.. Washington, DC: U.S. Dept of Health and Human Services, Public Health Service, Health Care Financing Administration; 1980;
  11. World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization; 1993;
  12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–944
  13. Khachaturian ZS. Diagnosis of Alzheimer’s disease. Arch Neurol. 1985;42:1097–1105
  14. Erkinjuntii T, Østbye T, Steenhuis R, Hachinski V. The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med. 1997;337:1667–1674
  15. U. S. General Accounting Office. Alzheimer’s disease: estimates of prevalence in the United States. Washington, DC: GAO/HEHS 98-16; 1998;
  16. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): part 1—clinical and neuropsychological assessment of Alzheimer’s disease. Neurology. 1989;39:1159–1165
  17. Mirra S, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): part II—standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991;41:479–486
  18. Davis PC, Gray L, Albert M, Wilkinson W, Hughes J, Heyman A, et al. Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): part III–reliability of a standardized MRI evaluation of Alzheimer’s disease. Neurology. 1992;42:1676–1680
  19. Mack JL, Patterson MB, Tariot PN. Behavior Rating Scale for Dementia (BRSD): development of test scales and presentation of data for 555 individuals with Alzheimer’s disease. J Geriatr Psych Neurol. 1999;12:211–223
  20. Tariot P, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, et al. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer’s Disease. Am J Psychiatry. 1995;152:1349–1357
  21. Silverman JM, Raiford K, Edland S, Fillenbaum G, Morris JC, Clark CM, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): part VI–family history assessment: a multicenter study of first-degree relatives of Alzheimer’s disease probands and nondemented spouse controls. Neurology. 1994;44:1253–1259
  22. Clark CM, Ewbank D, Lerner A, Doody R, Henderson VW, Panisset M, et al. The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer’s disease enrolled in the CERAD Study. Neurology. 1997;49:70–75
  23. Folstein MF, Folstein SE, McHugh PR. ‘Mini-Mental State’: a practical method of grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  24. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry. 1983;140:734–739
  25. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797–811
  26. Fillenbaum GG, Beekly D, Edland SD, Hughes JP, Heyman A, van Belle G. Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): development, data base structure and selected findings. Topics in Health Information Management. 1997;1:47–58
  27. Koss E, Peterson B, Fillenbaum GG. Determinants of attrition in a natural history study of Alzheimer’s disease. Alzheimer Dis Assoc Disord. 1999;13:209–215
  28. Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): part XI—clinical milestones in patients with Alzheimer’s disease followed over 3 years. Neurology. 1995;45:1451–1455
  29. McDaniel KD, Edland SD, Heyman A CERAD clinical investigators. Relationship between level of insight and severity of dementia in Alzheimer disease: Consortium to Establish a Registry for Alzheimer’s Disease. Alzheimer Dis Assoc Disord. 1995;9:101–104
  30. Neumann PJ, Araki SS, Arcelus A, Longo A, Papadopoulos G, Kosik KS, et al. Measuring Alzheimer’s disease progression with transition probabilities: estimates from CERAD. Neurology. 2001;57:957–964
  31. Weiner MF, Doody RS, Sairam R, Foster B, Liao TY. Prevalence and incidence of major depressive disorder in Alzheimer’s disease: findings from two databases. Dementia & Geriatric Cog Disord. 2002;13:8–12
  32. White H, Pieper C, Schmader K, Fillenbaum G. Weight change in Alzheimer’s disease. J Am Geriatr Soc. 1996;44:265–272
  33. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003;51:1451–1454
  34. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–572
  35. Barnett M. Standardization of Clinical Dementia Rating (CDR) among 23 Alzheimer’s disease study centers. Seattle, WA: Department of Biostatistics, University of Washington; 1992;Master’s thesis
  36. Mirra S, Gearing M, Nash F. Neuropathologic assessment of Alzheimer’s disease. Neurology. 1997;49(Suppl.3):S14–S16
  37. Welsh-Bohmer KA, Mohs RC. Neuropsychological assessment of Alzheimer’s disease. Neurology. 1997;49(Suppl 3):S11–S13
  38. Fillenbaum GG, Unverzagt FW, Ganguli M, Welsh-Bohmer KA, Heyman A. The CERAD Neuropsychological Battery: performance of representative community and tertiary care samples of African American and European American elderly. In:  Ferraro FR editors. Minority and cross-cultural aspects of neuropsychological assessment. Lisse, Netherlands: Swets and Zeitlinger; 2002;p. 45–62
  39. Ganguli M, Ratcliff G, DeKosky ST. Cognitive test scores in community-based older adults with and without dementia. Aging & Mental Health. 1997;1:176–180
  40. Morris JC, Edland S, Clark C, Galasko D, Koss E, Mohs R, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): part IV—rates of cognitive change, a longitudinal assessment of probable Alzheimer’s disease. Neurology. 1993;43:2457–2465
  41. Davis PC, Gearing M, Gray L, Mirra SS, Morris JC, Edland SD, et al. The CERAD experience, part VIII: neuroimaging-neuropathology correlates of temporal lobe changes in Alzheimer’s disease. Neurology. 1995;45:178–179
  42. Mirra S, Hart MN, Terry RD. Making the diagnosis of Alzheimer’s disease: a primer for practicing pathologists. Arch Pathol Lab Med. 1993;117:132–144
  43. Crain BJ, Mirra SS. The autopsy in cases of Alzheimer’s disease and other dementias. In:  Collins KA,  Hutchins GM editor. Autopsy performance & reporting. 2nd ed.. Northfield, IL: College of American Pathologists; 2003;p. 199–204
  44. Powers JM Autopsy Committee of the College of American Pathologists. Practice guidelines for autopsy pathology: autopsy procedures for brain, spinal cord, and neuromuscular system. Arch Pathol Lab Med. 1995;119:777–783
  45. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113–1124
  46. Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease: the National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging. 1997;18(Suppl):S1–S2
  47. Braak H, Braak E. Neuropathologic stageing of Alzheimer related changes. Acta Neuropathol. 1991;82:239–259
  48. Tierney MC, Fisher RH, Lewis AJ, Zorzitto ML, Snow WG, Reid DW, et al. The NINCDS-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer’s disease: a clinicopathologic study of 57 cases. Neurology. 1988;38:359–364
  49. Murayama S, Saito Y. Neuropathologic diagnostic criteria for Alzheimer’s disease. Neuropathology. 2004;24:254–260
  50. Nagi Z, Esiri MM, Hindley NJ, Joachim C, Morris JH, King EM, et al. Accuracy of clinical operational diagnostic criteria for Alzheimer’s disease in relation to different pathological diagnostic protocols. Dementia & Geriatric Cog Disord. 1998;9:219–226
  51. Newell KL, Hyman BT, Growdon JH, Hedley-White ET. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol. 1999;58:1147–1155
  52. Zaccai J, Ince P, Brayne C. Population-based neuropathological studies of dementia: design, methods and area of investigation: a systematic review. BMC Neurology. 2006;6:2;Available at: http://www.biomedcentral.com/1471-2377/6/2
  53. Whyte SR, Cullum CM, Hynan LS, Lacritz LH, Rosenberg RN, Weiner MF. Performance of elderly Native Americans and Caucasians on the CERAD Neuropsychological Battery. Alzheimer Dis Assoc Disord. 2005;19:74–78
  54. Aharon-Peretz J, Daskovski E, Mashiach T, Kliot D, Tomer R. Progression of dementia associated with lacunar infarctions. Dementia & Geriatric Cog Disord. 2003;16:71–77
  55. Aharon-Peretz J, Daskovski E, Mashiach T, Tomer R. Natural history of dementia associated with lacunar infarctions. J Neurol Sci. 2002;203-204:53–55
  56. Arango Lasprilla JC, Iglesias J, Lopera F. Neuropsychological study of familial Alzheimer’s disease caused by mutation E280A in the presenilin 1 gene. Am J Alzheimer’s Disease & Other Dementias. 2003;18:137–146
  57. Garcia-Ospina GP, Jimenez-Del Rio M, Lopera F, Velez-Pardo C. Neuronal DNA damage correlates with a positive detection of c-Jun, nuclear factor kB, p53 and Par-4 transcription factors in Alzheimer’s disease. Revista de Neurologia. 2003;36:1004–1010
  58. Ganguli M, Chandra V, Gilby J, Ratcliff G, Sharma SD, Pandav R, et al. Cognitive test performance in a community-based nondemented elderly sample in rural India: the Indo-U.S. Cross-National Dementia Epidemiology Study. Int Psychogeriatr. 1996;8:507–524
  59. Prince M, Acosta D, Chiu H, Scazufca M, Varghese M Dementia Research Group. Dementia diagnosis in developing countries: a cross-cultural validation study. Lancet. 2003;361:909–917
  60. Barnhart RL, van Belle G, Edland SD, Kukull W, Borson S, Raskind M, et al. Geographically overlapping Alzheimer’s Disease registries: comparisons and implications. J Geriatr Psychiatry Neurol. 1995;8:203–208
  61. Hughes JP, van Belle G, Kukull W, Larson EH, Teri L. On the uses of registries for Alzheimer Disease. Alzheimer Dis Assoc Disord. 1989;3:205–217
  62. Huppert FA, Brayne C, O’Connor DW. Dementia and normal aging. Cambridge, UK: Cambridge University Press; 1994;
  63. Morris JC. Mild cognitive impairment is early stage Alzheimer’s disease: time to revise diagnostic criteria. Arch Neurol. 2006;63:15–16
  64. Heyman A, Fillenbaum G, Nash F, eds. Consortium to Establish a Registry for Alzheimer’s Disease: the CERAD experience. Neurology 1997;49 (Suppl 3).
  65. Morris JC, Weintraub S, Chui HC, Cummings J, DeCarli C, Ferris S, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20:210–216
  66. Fillenbaum GG, Heyman A, Huber MS, Woodbury MA, Leiss J, Schmader KE, et al. The prevalence and three-year incidence of dementia in older Black and White community residents. J Clin Epidemiol. 1998;51:587–595
  67. White L, Petrovitch H, Ross GW, Masaki KH, Abbott RD, Teng EL, et al. Prevalence of dementia in older Japanese-American men living in Hawaii: the Honolulu-Asia Aging Study. JAMA. 1996;276:955–960
  68. Obadia Y, Rotily M, Degrand-Guillaud A, Guelain J, Ceccaldi M, Severo C, et al. The PREMAP Study: prevalence and risk factors of dementia and clinically diagnosed Alzheimer’s disease in Provence, France: prevalence of Alzheimer’s disease in Provence. Eur J Epidemiol. 1997;13:247–253
  69. Plassman BL, Langa KM, Fischer GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the Aging, Demographics, and Memory Study. Neuroepidemiology. 2007;29:125–132
  70. Breitner JCS, Wyse BW, Anthony JC, Welsh-Bohmer KA, Steffens DC, Norton MC, et al. APOE-ϵ4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology. 1999;53:321–331
  71. Miech RA, Breitner JCS, Zandi PP, Khachaturian AS, Anthony JC, Mayer L. Incidence of AD may decline in the early 90s for men, later for women: the Cache County study. Neurology. 2002;58:209–218
  72. Tschanz JT, Welsh-Bohmer KA, Lyketsos CG, Corcoran C, Green RC, Hayden K, et al. Conversion to dementia from mild cognitive disorder: the Cache County Study. Neurology. 2006;67:229–234
  73. Bienias JL, Beckett LA, Bennett DA, Wilson RS, Evans DA. Design of the Chicago Health and Aging Project (CHAP). J Alzheimers Dis. 2003;5:349–355
  74. Breitner JC, Welsh KA, Gau BA, McDonald WM, Steffens DC, Saunders AM, et al. Alzheimer’s disease in the National Academy of Sciences-National Research Council Registry of Aging Twin Veterans (III. Detection of cases, longitudinal results, and observations on twin concordance). Arch Neurol. 1995;52:763–771
  75. Plassman BL, Steffens DC, Burke JR, Welsh-Bohmer KA, Newman TN, Drosdick D, et al. Duke twins study of memory in aging in the NAS-NRC Twin Registry. Twin Res Hum Gene. 2006;9:950–957
  76. Hendrie HC, Osuntokun BO, Hall KS, Ogunniyi AO, Hui SL, Unverzagt FW, et al. The prevalence of Alzheimer’s disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry. 1995;152:1485–1492
  77. Hendrie HC, Ogunniyi A, Hall KS, Baiyewu O, Unverzagt FW, Gureje O, et al. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA. 2001;14:285;739–47
  78. Chandra V, Ganguli M, Pandav R, Johnston J, Belle S, DeKosky ST. Prevalence of Alzheimer’s disease and other dementias in rural India: the Indo-US study. Neurology. 1998;51:1000–1008
  79. Graves AB, Larson EB, Edland SD, Bowen JD, McCormick WC, McCurry SM, et al. Prevalence of dementia and its subtypes in the Japanese American population of King County, Washington State: the Kame Project. Am J Epidemiol. 1996;144:760–771
  80. Shin HY, Chung EK, Rhee JA, Yoon JS, Kim JM. Prevalence and related factors of dementia in an urban elderly population using a new screening method. [Korean] J Preventive Med Public Health / Yebang Uihakhoe Chi. 2005;38:351–358
  81. Ganguli M, Ratcliff G, Huff FJ, Belle S, Kancel JJ, Fischer L, et al. Effects of age, gender and education on cognitive tests in a rural elderly community sample: norms from the Monongahela Valley Independent Elders Survey. Neuroepidemiology. 1991;10:42–52
  82. Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer’s disease in late life: findings from the Nun Study. JAMA. 1996;275:528–532
  83. Snowdon DA. Aging and Alzheimer’s disease: lessons from the Nun Study. Gerontologist. 1997;37:150–156
  84. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198–205
  85. Bennett DA, Schneider JA, Buchman AS, Mendes de Leon CF, Bienias JL, Wilson RS. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology. 2005;25:163–175
  86. Lin RT, Lai CL, Tai CT, Liu CK, Yen YY, Howng SL. Prevalence and subtypes of dementia in southern Taiwan: impact of age, sex, education, and urbanization. J Int Neuropsychol Soc. 1998;160:67–75
  87. Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, et al. Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias. Neurology. 2000;55:1158–1166
  88. Alafuzoff I, Pikkarainen M, Al-Sarraj S, Arzberger T, Bell J, Bodi I, et al. Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol. 2006;65:740–757
  89. Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer’s disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias—Oxford Project to Investigate Memory and Aging. Int Psychogeriatr. 1998;10:271–302
  90. Neuropathology Group of the U.K. Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet. 2001;357:169–175
  91. Tractenberg RE, Gamst A, Thomas RG, Patterson M, Schneider LS, Thal LJ. Investigating emergent symptomatology as an outcome measure in a behavioral study of Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 2002;14:303–310
  92. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55:1271–1278Erratum in Neurology 2001;56:426
  93. Patterson MB, Mack JL, Mackell JA, Thomas R, Tariot P, Weiner M, et al. A longitudinal study of behavioral pathology across five levels of dementia severity in Alzheimer’s disease: the CERAD Behavior Rating Scale for Dementia—the Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S40–S44
  94. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health Initiative Memory Study. JAMA. 2004;291:2959–2968
  95. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2663–2672
  96. Shumaker SA, Legault C, Thal L, Wallace RB, Ockene JK, Hendrix SL, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study—a randomized controlled trial. JAMA. 2003;289:2651–2662
  97. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA. 2004;291:2947–2958
  98. Kryscio RJ, Mendiondo MS, Schmitt FA, Markesbery WR. Designing a large prevention trial: statistical issues. Stat Med. 2004;23:285–296
  99. Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA. Designing a brief Alzheimer screen. J Alzheimers Dis. 2003;5:391–398
  100. MacLennan AH, Henderson VW, Paine BJ, Mathias J, Ramsay EN, Ryan P, et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause. 2006;13:28–36
  101. Welsh K, Butters N, Hughes JP, Mohs RC, Heyman A. Detection and staging of dementia in Alzheimer’s disease: use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer’s Disease. Arch Neurol. 1992;49:448–452
  102. Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): part V—a normative study of the neuropsychological battery. Neurology. 1994;44:609–614
  103. Beeri MS, Schmeidler J, Sano M, Wang J, Lally R, Grossman H, et al. Age, gender, and education norms on the CERAD neuropsychological battery in the oldest old. Neurology. 2006;67:1006–1010
  104. Welsh KA, Fillenbaum G, Wilkinson W, Heyman A, Mohs RC, Stern Y, et al. Neuropsychological test performance in African-American and white patients with Alzheimer’s disease. Neurology. 1995;45:2207–2211
  105. Fillenbaum GG, Kuchibhatla M, Henderson VW, Clark CM, Taussig IM. Comparison of performance on the CERAD Neuropsychological Battery of Hispanic patients and cognitively normal controls at two sites. Clin Gerontologist. 2007;30:1–22
  106. Collie A, Shafiq-Antonacci R, Maruff P, Tyler P, Currie J. Norms and the effects of demographic variables on a neuropsychological battery for use in healthy ageing Australian populations. Aust N Z J Psychiatry. 1999;33:568–575
  107. Bertolucci PHF, Okamoto IH, Brucki SMD, Siviero MO, Neto JT, Ramos LR. Applicability of the CERAD Neuropsychological Battery to Brazilian elderly. Arq Neuropsiquiatr. 2001;59:532–536
  108. Karrasch M, Laine M. Age, education and test performance on the Finnish CERAD. Acta Neurol Scand. 2003;108:97–101
  109. Karrasch M, Sinerva E, Gronholm P, Rinne J, Laine M. CERAD test performances in amnestic mild cognitive impairment and Alzheimer’s disease. Acta Neurol Scand. 2005;111:172–179
  110. Unverzagt FW, Morgan OS, Thesiger CH, Eldemire DA, Luseko J, Pokuri S, et al. Clinical utility of CERAD neuropsychological battery in elderly Jamaicans. J Int Neuropsychol Soc. 1999;5:255–259
  111. Lee DY, Lee KU, Lee JH, Kim KW, Jhoo JH, Kim SY, et al. A normative study of the CERAD neuropsychological assessment battery in the Korean elderly. J Int Neuropsychol Soc. 2004;10:72–81
  112. Guruje O, Unverzargt FW, Osuntokun BO, Hendrie HC, Baiyewu O, Ogunniyi A, et al. The CERAD Neuropsychological Test Battery: norms from a Yoruba-speaking Nigerian sample. West African J Med. 1995;14:29–33
  113. Berres M, Monsch AU, Bernasconi F, Thalmann B, Stahelin HB. Normal ranges of neuropsychological tests for the diagnosis of Alzheimer’s disease. Studies in Health Technology Information. 2000;77:195–199
  114. Stewart R, Richards M, Brayne C, Mann A. Cognitive function in UK community-dwelling African Caribbean elders: normative data for a test battery. Int J Geriatric Psychiatry. 2001;16:518–527
  115. Unverzagt FW, Hall KS, Torke AM, Rediger JD, Mercado N, Gureje O, et al. Effects of age, education, and gender on CERAD neuropsychological test performance in an African–American sample. Clin Neuropsychol. 1996;10:180–190
  116. Fillenbaum GG, McCurry SM, Kuchibhatla M, Masaki KH, Borenstein AR, Foley DJ, et al. Performance on the CERAD neuropsychology battery of two samples of Japanese-American elders: norms for persons with and without dementia. J Int Neuropsychol Soc. 2005;11:192–201
  117. McCurry SM, Gibbons LE, Uomoto JM, Thompson ML, Graves AB, Edland SD, et al. Neuropsychological test performance in a cognitively intact sample of older Japanese American adults. Arch Clin Neuropsychol. 2001;16:447–459

 With the exception of the senior author (Dr Heyman), who was the Principal Investigator of CERAD, and the first author, who was the Project Director, the order of authorship reflects the order of development of CERAD’s primary assessments. The Methodology and Data Management Center (Dr van Belle) and the Clinical (Dr Morris) and Neuropsychology (Dr Mohs) batteries were developed simultaneously. These were followed by the Neuropathology protocol (Dr Mirra), the Neuroimaging protocol (Dr Davis), the Behavior Rating Scale for Dementia (Dr Tariot), evaluation of family history (Dr Silverman), and structured assessment of extrapyramidal dysfunction in AD (Dr Clark).

PII: S1552-5260(07)00616-4

doi: 10.1016/j.jalz.2007.08.005

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 2 , Pages 96-109 , March 2008

Article Tools

* Image Usage & Resolution